GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow
Executive Summary
Arexvy will launch in the US in time for the fall 2023 RSV season for adults 60 and older, GSK said. Pfizer’s Abrysvo is also pending at the FDA.
You may also be interested in...
Abrysvo Launch A Bright Spot For Pfizer In A Third Quarter Reset
The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.
GSK Points To Merck’s Gardasil Success In Deal With Zhifei For Shingrix
The British drug maker hopes the partnership for the Chinese market will accelerate its efforts to reach its goal of £4bn or more in sales of Shingrix by 2026.
Bavarian Drops RSV Program After Phase III Flop
The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.